bluebird bio Inc. is a bluebird bio inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases.
bluebird bio Inc. (BLUE) had a good day on the market for Monday August 17 as shares jumped 4.34% to close at $62.26. About 577,389 shares traded hands on 7,896 trades for the day, compared with an average daily volume of n/a shares out of a total float of 66.22 million. After opening the trading day at $60.05, shares of bluebird bio Inc. stayed within a range of $62.74 to $59.36.
With today’s gains, bluebird bio Inc. now has a market cap of $4.12 billion. Shares of bluebird bio Inc. have been trading within a range of $124.16 and $38.96 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company’s gene therapy procedures aim to genetically modify a patient’s cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird’s revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.
bluebird bio Inc. is based out of Cambridge, MA and has some 1,153 employees. Its CEO is Nick Leschly.